vs
Pacira BioSciences, Inc.（PCRX）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是RESOURCES CONNECTION, INC.的1.5倍（$177.4M vs $117.7M），Pacira BioSciences, Inc.净利率更高（1.6% vs -10.8%，领先12.4%），Pacira BioSciences, Inc.同比增速更快（5.0% vs -19.2%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -11.8%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
PCRX vs RGP — 直观对比
营收规模更大
PCRX
是对方的1.5倍
$117.7M
营收增速更快
PCRX
高出24.2%
-19.2%
净利率更高
PCRX
高出12.4%
-10.8%
两年增速更快
PCRX
近两年复合增速
-11.8%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $117.7M |
| 净利润 | $2.9M | $-12.7M |
| 毛利率 | — | 37.1% |
| 营业利润率 | 3.9% | -10.3% |
| 净利率 | 1.6% | -10.8% |
| 营收同比 | 5.0% | -19.2% |
| 净利润同比 | — | 81.6% |
| 每股收益（稀释后） | $0.07 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXRGP
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $117.7M | ||
| Q3 25 | $179.5M | $120.2M | ||
| Q2 25 | $181.1M | $139.3M | ||
| Q1 25 | $168.9M | $129.4M | ||
| Q4 24 | $187.3M | $145.6M | ||
| Q3 24 | $168.6M | $136.9M | ||
| Q2 24 | $178.0M | $148.2M |
净利润PCRXRGP
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-12.7M | ||
| Q3 25 | $5.4M | $-2.4M | ||
| Q2 25 | $-4.8M | $-73.3M | ||
| Q1 25 | $4.8M | $-44.1M | ||
| Q4 24 | — | $-68.7M | ||
| Q3 24 | $-143.5M | $-5.7M | ||
| Q2 24 | $18.9M | $10.5M |
毛利率PCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 37.1% | ||
| Q3 25 | 80.9% | 39.5% | ||
| Q2 25 | 77.4% | 40.2% | ||
| Q1 25 | 79.7% | 35.1% | ||
| Q4 24 | 78.7% | 38.5% | ||
| Q3 24 | 76.9% | 36.5% | ||
| Q2 24 | 75.1% | 40.2% |
营业利润率PCRXRGP
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -10.3% | ||
| Q3 25 | 3.5% | -1.7% | ||
| Q2 25 | 4.7% | -47.0% | ||
| Q1 25 | 1.2% | -38.4% | ||
| Q4 24 | 13.2% | -52.7% | ||
| Q3 24 | -82.8% | -3.5% | ||
| Q2 24 | 15.9% | 7.6% |
净利率PCRXRGP
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -10.8% | ||
| Q3 25 | 3.0% | -2.0% | ||
| Q2 25 | -2.7% | -52.6% | ||
| Q1 25 | 2.8% | -34.0% | ||
| Q4 24 | — | -47.2% | ||
| Q3 24 | -85.1% | -4.2% | ||
| Q2 24 | 10.6% | 7.1% |
每股收益（稀释后）PCRXRGP
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.38 | ||
| Q3 25 | $0.12 | $-0.07 | ||
| Q2 25 | $-0.11 | $-2.21 | ||
| Q1 25 | $0.10 | $-1.34 | ||
| Q4 24 | $0.38 | $-2.08 | ||
| Q3 24 | $-3.11 | $-0.17 | ||
| Q2 24 | $0.39 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $89.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $194.6M |
| 总资产 | $1.2B | $289.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXRGP
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $89.8M | ||
| Q3 25 | $246.3M | $77.5M | ||
| Q2 25 | $445.9M | $86.1M | ||
| Q1 25 | $493.6M | $72.5M | ||
| Q4 24 | $484.6M | $78.2M | ||
| Q3 24 | $453.8M | $89.6M | ||
| Q2 24 | $404.2M | $108.9M |
总债务PCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXRGP
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $194.6M | ||
| Q3 25 | $727.2M | $206.4M | ||
| Q2 25 | $757.8M | $207.1M | ||
| Q1 25 | $798.5M | $277.8M | ||
| Q4 24 | $778.3M | $325.7M | ||
| Q3 24 | $749.6M | $407.2M | ||
| Q2 24 | $879.3M | $418.8M |
总资产PCRXRGP
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $289.3M | ||
| Q3 25 | $1.3B | $287.2M | ||
| Q2 25 | $1.5B | $304.7M | ||
| Q1 25 | $1.6B | $375.6M | ||
| Q4 24 | $1.6B | $424.9M | ||
| Q3 24 | $1.5B | $512.9M | ||
| Q2 24 | $1.6B | $510.9M |
负债/权益比PCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $15.9M |
| 自由现金流经营现金流 - 资本支出 | — | $15.6M |
| 自由现金流率自由现金流/营收 | — | 13.2% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $24.3M |
8季度趋势，按日历期对齐
经营现金流PCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $15.9M | ||
| Q3 25 | $60.8M | $-7.8M | ||
| Q2 25 | $12.0M | $16.8M | ||
| Q1 25 | $35.5M | $659.0K | ||
| Q4 24 | $33.1M | $1.8M | ||
| Q3 24 | $53.9M | $-309.0K | ||
| Q2 24 | $53.2M | $3.2M |
自由现金流PCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $15.6M | ||
| Q3 25 | $57.0M | $-8.0M | ||
| Q2 25 | $9.3M | $16.5M | ||
| Q1 25 | $26.9M | $238.0K | ||
| Q4 24 | $31.0M | $61.0K | ||
| Q3 24 | $49.8M | $-575.0K | ||
| Q2 24 | $51.6M | $3.0M |
自由现金流率PCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 13.2% | ||
| Q3 25 | 31.7% | -6.6% | ||
| Q2 25 | 5.1% | 11.8% | ||
| Q1 25 | 15.9% | 0.2% | ||
| Q4 24 | 16.6% | 0.0% | ||
| Q3 24 | 29.6% | -0.4% | ||
| Q2 24 | 29.0% | 2.1% |
资本支出强度PCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 2.2% | 0.1% | ||
| Q2 25 | 1.5% | 0.2% | ||
| Q1 25 | 5.1% | 0.3% | ||
| Q4 24 | 1.1% | 1.2% | ||
| Q3 24 | 2.4% | 0.2% | ||
| Q2 24 | 0.9% | 0.1% |
现金转化率PCRXRGP
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | 0.30× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
